Postagem em destaque

CRISPR crunch

Genetic engineering CRISPR crunch A row over who invented a new gene-editing technique heats up Feb 20th 2016  |  WASHINGTON, DC  |...

sábado, 23 de janeiro de 2016

News from PatentScope

November 19, 2015
Patent data in Korean of the national patent collection of the Republic of Korea is now available in WIPO’s global patent search system PATENTSCOPE.
It includes about 3,400,000 records: bibliographic data, searchable full-text and drawings in Korean with front file data in the new WIPO standard ST96 PDF. Regarding new data, it will become available within a month after their first publication in KIPRIS, the patent search system of the Korean Patent Office (KIPO). For users who do not know the Korean language, the in-house developed tool CLIR will allow them to search in the descriptions and claims in Korean.
The addition of patent data in Korean of the Republic of Korea brings to:
  • over 50 million the total number of patent documents
  • 5 the number of IP5 offices whose full-text is searchable
in the PATENTSCOPE search system.


PATENTSCOPE Translation Now Works with Long Chinese Documents

September 22, 2015
WIPO Translate, the machine translation tool developed by WIPO and available within the PATENTSCOPE user interface, now offers industry-leading translation of full-length Chinese documents into English and vice versa.
Users can now benefit from real-time, automatic translation of long documents. Moreover, WIPO translate has been trained exclusively on Chinese/English patent texts and independent evaluation tools such as BLEU show that it is more accurate than other publicly available solutions (e.g.Google Translate, Microsoft-Bing translate or Baidu translate). As a result, users can get a better, clearer idea of the nature of an invention than may be possible with external translation tools.
WIPO Translate operates with a secure https protocol, meaning that translation activity remains private and cannot be accessed by any third party.


segunda-feira, 18 de janeiro de 2016

Amazing!!! Training computers to "think" by simulating brain processes

Training computers to “think” by simulating brain processes


We’ve used one interesting type of machine learning, called an artificial neural network (ANN), in our own lab. Brains are highly interconnected networks of neurons, which communicate by sending electric pulses through the neural wiring. Similarly, an ANN simulates in the computer a network of neurons as they turn on and off in response to other neurons' signals.

By applying algorithms that mimic the processes of real neurons, we can make the network learn to solve many types of problems. Google uses a powerful ANN for its now famous Deep Dream project where computers can classify and even create images.
Our group studies the immune system, with the goal of figuring out new therapies for cancer. We’ve used ANN computational models to study short surface protein-codes our immune cells use to determine whether something is foreign to our body and thus should be attacked. If we understand more about how our immune cells (such as T-cells) differentiate between normal/self and abnormal/foreign cells, we can design better vaccines and therapies.

We scoured publicly available catalogs of thousands of protein-codes identified by researchers over the years. We divided this big data set into two: normal self-protein codes derived from healthy human cells, and abnormal protein-codes derived from viruses, tumors and bacteria. Then we turned to an artificial neural network developed in our lab.

Once we fed the protein-codes into the ANN, the algorithm was able to identify fundamental differences between normal and abnormal protein-codes. It would be tough for people to keep track of these kinds of biological phenomena – there are literally thousands of these protein codes to analyze in the big data set. It takes a machine to wrangle these complex problems and define new biology.

Predictions via machine learning

The most important application of machine learning in biology is its utility in making predictions based on big data. Computer-based predictions can make sense of big data, test hypotheses and save precious time and resources.
César de Nostredame, nostradamus
No need for Nostradamus and his predictions; we have computers now.
Credit: César de Nostredame
For instance, in our field of T-cell biology, knowing which viral protein-codes to target is critical in developing vaccines and treatments. But there are so many individual protein-codes from any given virus that it’s very expensive and difficult to experimentally test each one.
Instead, we trained the artificial neural network to help the machine learn all the important biochemical characteristics of the two types of protein-codes – normal versus abnormal. Then we asked the model to “predict” which new viral protein codes resemble the “abnormal” category and could be seen by T-cells and thus, the immune system. We tested the ANN model on different virus proteins that have never been studied before.
Sure enough, like a diligent student eager to please the teacher, the neural network was able to accurately identify the majority of such T-cell-activating protein-codes within this virus. We also experimentally tested the protein codes it flagged to validate the accuracy of the ANN’s predictions. Using this neural network model, a scientist can thus rapidly predict all the important short protein-codes from a harmful virus and test them to develop a treatment or a vaccine, instead of guessing and testing them individually.

Implementing machine learning wisely

Thanks to constant refining, big data science and machine learning are increasingly becoming indispensable for any kind of scientific research. The possibilities for using computers to train and predict in biology are almost endless. From figuring out which combination of biomarkers are best for detecting a disease to understanding why only some patients benefit from a particular cancer treatment, mining big data sets using computers has become a valuable route for research.
Of course, there are limitations. The biggest problem with big data science is the data themselves. If data obtained by -omics studies are faulty to begin with, or based on shoddy science, the machines will get trained on bad data – leading to poor predictions. The student is only as good as the teacher.
Because computers are not sentient (yet), they can in their quest for patterns come up with them even when none exist, giving rise again, to bad data and nonreproducible science.
And some researchers have raised concerns about computers becoming black boxes of data for scientists who don’t clearly understand the manipulations and machinations they carry out on their behalf.
In spite of these problems, the benefits of big data and machines will continue to make them valuable partners in scientific research. With caveats in mind, we are uniquely poised to understand biology through the eyes of a machine.
Sri Krishna, PhD Candidate, Biological Design, School of Biological and Health Systems Engineering, Arizona State University and Diego Chowell, PhD Student in Applied Mathematics, Arizona State University
This article was originally published on The Conversation. Read theoriginal article. Follow all of the Expert Voices issues and debates — and become part of the discussion — on FacebookTwitter and Google +. The views expressed are those of the author and do not necessarily reflect the views of the publisher. This version of the article was originally published on Live Science.

quarta-feira, 13 de janeiro de 2016

New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market.
The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development. 
Each year, CDER approves a wide range of new drugs and biological products. Some of these products are innovative new products that never before have been used in clinical practice. Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace.
Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act.